Introduction
Dysfunction of cardiac lymphatic network can lead to myocardial edema and persistent inflammation. Selective stimulation of cardiac lymphangiogenesis has been shown to reduce myocardial edema and fibrosis, and contribute to the improvement of cardiac function following myocardial ischemia and
infarction. This invention indicates that fluorescent gold nanoclusters (FANC) profoundly promote lymphangiogenesis property in both in vitro and in vivo models. FANC showed the therapeutic effect in the isoproterenol (ISO)- induced heart failure model. Treatment of FANC significantly improved cardiac
hypertrophy, fractional shortening, and myocardial systolic velocity in ISO- treated mice. This invention provides the application of FANC for stimulation of lymphangiogenesis in the treatment of lymphangiogenesis-associated ischaemic heart disease.
Features / strengths
Therapeutic lymphangiogenesis is a promising new approach to attenuate the development of heart failure. Our findings reveal that FANC promote lymphogenesis to ameliorate heart injury, fibrosis and inflammatory responses in animal model. The metabolism of FANC is not via liver, no accumulation
and no hepatic toxicity. For one year of toxicity study, FANC did not affect fertility, no teratogenicity, no accumulation in vital organs, indicating their safety and biocomparability. This patent invention reveals a novel mechanism by which FANC activates lymphangiogenesis and is subsequently used for the treatment of heart failure. Further development of FANC as a drug will enhance its potential as a new treatment for diseases related to lymphangiogenesis.
Specification in detail
Under development
Seek of partners for business cooperation
